Icaritin/ZKAB 001
Alternative Names: IC-162/ZKAB-001; Icaritin/STI-A1014; Icaritin/ZKAB001; PD-L1 monoclonal antibody - Lees Pharmaceutical Holdings; SNG-162/STI-A1014; SNG-162/ZKAB-001; STI-A1014/Icaritin; STI-A1014/SNG-162; ZKAB-001/IC-162; ZKAB-001/IcaritinLatest Information Update: 28 Dec 2021
At a glance
- Originator Lees Pharmaceutical Holdings; Shenogen Pharma
- Developer Lee's Pharmaceutical; Shenogen Pharma
- Class Antineoplastics; Benzopyrans; Flavonoids; Monoclonal antibodies; Phenyl ethers; Small molecules
- Mechanism of Action Estrogen receptor alpha modulators; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer